Table 3 Patient and tumor characteristics for patients tested with Oncotype DX® (N = 44), MammaPrint® (N = 28), or Prosigna® (N = 57).
Characteristic | ODX (N = 44) | MP (N = 28) | Prosigna (N = 57) | Total (N = 129) |
|---|---|---|---|---|
Age (years) median | 57 (25–76) | 58 (38–78) | 51 (37–73) | 56 (25–78) |
Pre-/perimenopausal | 14 (32%) | 9 (32%) | 25 (44%) | 48 (37%) |
Postmenopausal | 30 (68%) | 17 (61%) | 29 (51%) | 76 (59%) |
Unknown | 0 (0%) | 2 (7%) | 3 (5%) | 5 (4%) |
Tumor type | ||||
ILC | 8 (18%) | 4 (14%) | 7 (12%) | 19 (15%) |
IDC | 34 (77%) | 24 (86%) | 49 (86%) | 107 (83%) |
Mixed ILC-IDC | 0 (0%) | 0 (0%) | 1 (2%) | 1 (1%) |
Mucinous | 1 (2%) | 0 (0%) | 0 (0%) | 1 (1%) |
Tubular | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
IDC + micropapillary | 1 (2%) | 0 (0%) | 0 (0%) | 1 (1%) |
Tumor size | ||||
≤2 cm (pT1) | 12 (27%) | 9 (32%) | 18 (32%) | 39 (30%) |
>2–5 cm (pT2) | 30 (68%) | 17 (61%) | 34 (60%) | 81 (63%) |
>5 cm (pT3) | 2 (5%) | 2 (7%) | 5 (9%) | 9 (7%) |
Histological grade | ||||
1 | 3 (7%) | 3 (11%) | 3 (5%) | 9 (7%) |
2 | 24 (55%) | 17 (61%) | 45 (79%) | 86 (67%) |
3 | 17 (39%) | 8 (29%) | 9 (16%) | 34 (26%) |
PR status | ||||
Positive | 38 (86%) | 23 (82%) | 47 (82%) | 108 (84%) |
Negative | 6 (14%) | 5 (18%) | 10 (18%) | 21 (16%) |
Focality | ||||
Unifocal | 34 (77%) | 24 (86%) | 43 (75%) | 101 (78%) |
Multifocal | 10 (23%) | 4 (14%) | 14 (25%) | 28 (22%) |
Nodal status | ||||
pN0 | 29 (66%) | 14 (50%) | 29 (51%) | 72 (56%) |
1 positive lymph node | 7 (16%) | 11 (39%) | 16 (28%) | 35 (27%) |
2 positive lymph nodes | 8 (18%) | 3 (11%) | 8 (14%) | 18 (14%) |
3 positive lymph nodes | 0 (0%) | 0 (0%) | 3 (5%) | 3 (2%) |
4 positive lymph nodes | 0 (0%) | 0 (0%) | 1 (2%) | 1 (1%) |
Ki-67% | ||||
≤10 | 20 (45%) | 6 (21%) | 24 (42%) | 50 (39%) |
11–20 | 8 (18%) | 12 (43%) | 14 (25%) | 34 (26%) |
≥20 | 16 (36%) | 9 (32%) | 19 (33%) | 44 (34%) |
Unknown | 0 (0%) | 1 (4%) | 0 (0%) | 1 (1%) |
Intrinsic molecular subtype | ||||
Luminal A | N.A. | 16 (57%) | 36 (63%) | N.A. |
Luminal B | N.A. | 12 (43%) | 18 (32%) | N.A. |
HER2-enriched | N.A. | 0 (0%) | 1 (2%) | N.A. |
Basal-like | N.A. | 0 (0%) | 2 (4%) | N.A. |
